Endo International plc Announces Pricing of Private Offering Of Senior Notes

 Endo International plc Announces Pricing of Private Offering Of Senior Notes

PR Newswire

DUBLIN, June 25, 2014

DUBLIN, June 25, 2014 /PRNewswire/ --Endo International plc (NASDAQ: ENDP)
(TSX: ENL) ("Endo") today announced that Endo Finance LLC and Endo Finco Inc.,
its wholly-owned subsidiaries, priced $750 million aggregate principal amount
of 5.375% senior notes due January 2023 at an issue price of $1,000 per $1,000
principal amount in connection with their previously announced private
offering. The notes will be unsecured, unsubordinated obligations of Endo
Finance LLC and Endo Finco Inc. and will be guaranteed by Endo Limited, a
wholly-owned subsidiary of Endo, and certain of Endo Limited's direct and
indirect subsidiaries.

Endo intends to use the net proceeds from the offering for general corporate
purposes, which may include acquisitions, including the acquisition of Dava
Pharmaceuticals, Inc.

The notes and the related guarantees have not been registered under the
Securities Act of 1933, as amended, or any applicable state or foreign
securities laws, and will be offered only to qualified institutional buyers in
reliance on Rule 144A, and outside the United States in compliance with
Regulation S under the Securities Act. Unless so registered, the notes and the
related guarantees may not be offered or sold in the United States except
pursuant to an exemption from the registration requirements of the Securities
Act and applicable state securities laws. This press release will not
constitute an offer to sell or a solicitation of an offer to buy any notes or
any other securities.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and Canadian securities
legislation. These forward-looking statements include the following: Endo's
intention to offer $[750] million in aggregate principal amount of notes and
Endo's intention regarding the use of the net proceeds of the offering.
Statements including words such as "believes," "expects," "anticipates,"
"intends," "estimates," "plan," "will," "may," "look forward," "intend,"
"guidance," "future" or similar expressions are forward-looking statements.
Because these statements reflect our current views, expectations and beliefs
concerning future events, these forward-looking statements involve risks and
uncertainties. Although Endo believes that these forward-looking statements
and information are based upon reasonable assumptions and expectations,
readers should not place undue reliance on them, or any other forward looking
statements or information in this news release. Investors should note that
many factors, as more fully described in the documents filed by Endo with
securities regulators in the United States and Canada including under the
caption "Risk Factors" in Endo Health Solutions Inc.'s ("EHSI") Form 10-K, and
Endo's Form 10-Q and Form 8-K filings, as applicable, with the Securities and
Exchange Commission and with securities regulators in Canada on the System for
Electronic Document Analysis and Retrieval ("SEDAR") and as otherwise
enumerated herein or therein, could affect Endo's future financial results and
could cause Endo's actual results to differ materially from those expressed in
forward-looking statements contained in EHSI's Annual Report on Form 10-K. The
forward-looking statements in this press release are qualified by these risk
factors. These are factors that, individually or in the aggregate, could cause
our actual results to differ materially from expected and historical results.
Endo assumes no obligation to publicly update any forward-looking statements,
whether as a result of new information, future developments or otherwise,
except as may be required under applicable securities law.

SOURCE Endo International plc

Contact: Investors/Media: Blaine Davis, (484) 216-7158, +353-1-669-6635, or
Investors: Jonathan Neely, (484) 216-6645, Media: Brian O'Donnell, (484)
Press spacebar to pause and continue. Press esc to stop.